<a href="https://www.fiercebiotech.com/biotech/alnylam-pays-inceptive-30m-transform-sirna-design-ai-pioneer" hreflang="en">Alnylam pens $2B deal with Inceptive to transform siRNA design with AI pioneer</a>
Alnylam has entered a $2 billion partnership with Inceptive Nucleics, co-founded by AI pioneer Jakob Uszkoreit, to enhance siRNA drug design using artificial intelligence. The collaboration aims to leverage AI for modeling target mRNAs and improving the potency and efficacy of RNA-based therapeutics.
The partnership between Alnylam and Inceptive highlights a significant move in AI-driven drug design, specifically in using AI to enhance the design of siRNA therapeutics. This $2 billion deal underscores the potential of integrating AI models trained on a mix of sequence, function, and structure data to adapt quickly and generate insights from small datasets, potentially transforming the landscape of RNAi therapeutics. For professionals tracking AI drug discovery, this represents a crucial development to watch, emphasizing the growing importance of AI in precision medicine and biopharma partnerships.